Barclays Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $626
Benzinga Newsdesk 10 hours ago
Analyst RatingsNewsPrice TargetHot
Barclays analyst Eliana Merle maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $617 to $626.
Barclays analyst Eliana Merle maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $617 to $626.